Literature DB >> 9672542

Validation of a treatment-based classification system for individuals with facial neuromotor disorders.

J M VanSwearingen1, J S Brach.   

Abstract

BACKGROUND AND
PURPOSE: A method for linking treatments to signs and symptoms of facial neuromotor disorders is needed. We describe the construct validation of a treatment-based classification system for facial neuromotor disorders. SUBJECTS AND METHODS: Based on physical signs and symptoms, 148 patients (mean age = 48.9 years, SD = 16.1, range = 20-93) were assigned to treatment-based categories. The pattern of impairment and disability was compared with clinic expectations.
RESULTS: The distribution of impairment and disability scores demonstrated the expected signs and symptoms of the treatment-based categories. Confirmatory principal-components factor analysis indicated 4 factors, corresponding to the treatment-based categories; the factor loadings confirmed the presence of the key sign or symptom characteristic of the categories. CONCLUSION AND DISCUSSION: Classifying facial neuromotor disorders into treatment-based categories appears to be a valid method for categorizing patients with specific impairments or disabilities and may be useful in linking treatments to outcomes.

Entities:  

Mesh:

Year:  1998        PMID: 9672542     DOI: 10.1093/ptj/78.7.678

Source DB:  PubMed          Journal:  Phys Ther        ISSN: 0031-9023


  2 in total

1.  Functional Outcome and Quality of Life After Hypoglossal-Facial Jump Nerve Suture.

Authors:  Gerd Fabian Volk; Maren Geitner; Katharina Geißler; Jovanna Thielker; Ashraf Raslan; Oliver Mothes; Christian Dobel; Orlando Guntinas-Lichius
Journal:  Front Surg       Date:  2020-03-19

2.  Multidisciplinary Care of Patients with Facial Palsy: Treatment of 1220 Patients in a German Facial Nerve Center.

Authors:  Jonathan Steinhäuser; Gerd Fabian Volk; Jovanna Thielker; Maren Geitner; Anna-Maria Kuttenreich; Carsten M Klingner; Christian Dobel; Orlando Guntinas-Lichius
Journal:  J Clin Med       Date:  2022-01-14       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.